We are analyzing https://link.springer.com/article/10.1007/s00005-017-0480-8.

Title:
Tumor-Associated Macrophages as Target for Antitumor Therapy | Archivum Immunologiae et Therapiae Experimentalis
Description:
It is well known that the microenvironment of solid tumors is rich in inflammatory cells that influence tumor growth and development. Macrophages, called tumor-associated macrophages (TAMs), are the most abundant immune cell population present in tumor tissue. Several studies have demonstrated that the density of TAMs is associated with a poor prognosis and positively correlates with tumor growth. Several studies have proved that TAMs may activate and protect tumor stem cells, stimulate their proliferation as well as promote angiogenesis and metastasis. Furthermore, TAMs-derived cytokines and other proteins, such as CCL-17, CCL-22, TGF-β, IL-10, arginase 1, and galectin-3, make a significant contribution to immunosuppression. Since TAMs influence various aspects of cancer progression, there are many attempts to use them as a target for immunotherapy. The numerous studies have shown that the primary tumor growth and the number of metastatic sites can be significantly decreased by decreasing the population of macrophages in tumor tissue, for example, by blocking recruitment of monocytes or eliminating TAMs already present in the tumor tissue. Moreover, there are attempts at reprogramming TAMs into proinflammatory M1 macrophages or neutralizing the protumoral products of TAMs. Another approach uses TAMs for anticancer drug delivery into the tumor environment. In this review, we would like to summarize the clinical and preclinical trials that were focused on macrophages as a target for anticancer therapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, cancer, google, scholar, article, macrophages, tumor, cas, tams, central, cells, clinical, growth, cell, tumors, macrophage, antitumor, studies, treatment, tumorassociated, antibody, phase, res, target, therapy, patients, nct, proved, ccl, study, shown, model, breast, mice, tissue, activation, receptor, metastasis, progression, trials, human, immune, delivery, factor, activity, anticancer, number, targeting, vivo, immunol,

Topics {✒️}

milk-fat globule egf-viii cd8+/cd4+ t-cell ratio post-sepsis-induced melanoma progression anti-csf-1r antibody reveals katarzyna sawa-wejksza article sawa-wejksza tyrosine kinase inhibitors tumor-targeted anti-angiogenic nanomedicine live-attenuated listeria vaccine bone-marrow-derived immune cells host-produced histidine-rich glycoprotein platelet-derived growth factor myeloid-derived suppressor cells von bergwelt-baildon ms maria curie-skłodowska university cancer stem/initiating cells b16 melanoma-bearing mice biohybrid rnai-peptide nanoparticles anti-csf-1r antibody inducing double-strand breaks osteoclast-mediated bone resorption covalent calcium cross-linking article download pdf engineered tumor-infiltrating macrophages attenuated listeria monocytogenes agonist anti-cd40 antibody anti-tumour strategies aiming m2 anti-inflammatory/regulatory macrophages legumain-expressing dna vaccine anti-10ra antisense oligonucleotides myeloid-derived suppressive cells clodronate-loaded liposomes augmented anti-interleukin-6 monoclonal antibody folate receptor-β expression kandefer-szerszeń transcription factor nf-κb interferon-α activates immunity table 1 anti-tumor strategies biohybrid sirna-peptide nanoparticles trabectedin-resistant tumor cells nuclear factor-kappab activity clodronate-liposome-mediated depletion clodronate-loaded liposomes increased ccl2-ccr2 signaling axis m2 macrophage-targeting peptide microrna-26a suppresses recruitment cd40-activated apc cells chimeric murine-human antibody anti-cd11b mab treatment cd40-expressing solid tumors

Questions {❓}

Bissell MJ, Hines WC (2011) Why don’t we get more cancer?
Cabarcas SM, Mathews LA, Farrar WL (2011) The cancer stem cell niche–there goes the neighborhood?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor-Associated Macrophages as Target for Antitumor Therapy
         description:It is well known that the microenvironment of solid tumors is rich in inflammatory cells that influence tumor growth and development. Macrophages, called tumor-associated macrophages (TAMs), are the most abundant immune cell population present in tumor tissue. Several studies have demonstrated that the density of TAMs is associated with a poor prognosis and positively correlates with tumor growth. Several studies have proved that TAMs may activate and protect tumor stem cells, stimulate their proliferation as well as promote angiogenesis and metastasis. Furthermore, TAMs-derived cytokines and other proteins, such as CCL-17, CCL-22, TGF-β, IL-10, arginase 1, and galectin-3, make a significant contribution to immunosuppression. Since TAMs influence various aspects of cancer progression, there are many attempts to use them as a target for immunotherapy. The numerous studies have shown that the primary tumor growth and the number of metastatic sites can be significantly decreased by decreasing the population of macrophages in tumor tissue, for example, by blocking recruitment of monocytes or eliminating TAMs already present in the tumor tissue. Moreover, there are attempts at reprogramming TAMs into proinflammatory M1 macrophages or neutralizing the protumoral products of TAMs. Another approach uses TAMs for anticancer drug delivery into the tumor environment. In this review, we would like to summarize the clinical and preclinical trials that were focused on macrophages as a target for anticancer therapies.
         datePublished:2017-06-28T00:00:00Z
         dateModified:2017-06-28T00:00:00Z
         pageStart:97
         pageEnd:111
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00005-017-0480-8
         keywords:
            Tumor-associated macrophages
            TAMs
            Cancer therapies
            Immunotherapy
            Tumor
            Immunology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Archivum Immunologiae et Therapiae Experimentalis
            issn:
               1661-4917
               0004-069X
            volumeNumber:66
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Katarzyna Sawa-Wejksza
               url:http://orcid.org/0000-0001-5495-1838
               affiliation:
                     name:Maria Curie-Skłodowska University
                     address:
                        name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Martyna Kandefer-Szerszeń
               affiliation:
                     name:Maria Curie-Skłodowska University
                     address:
                        name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor-Associated Macrophages as Target for Antitumor Therapy
      description:It is well known that the microenvironment of solid tumors is rich in inflammatory cells that influence tumor growth and development. Macrophages, called tumor-associated macrophages (TAMs), are the most abundant immune cell population present in tumor tissue. Several studies have demonstrated that the density of TAMs is associated with a poor prognosis and positively correlates with tumor growth. Several studies have proved that TAMs may activate and protect tumor stem cells, stimulate their proliferation as well as promote angiogenesis and metastasis. Furthermore, TAMs-derived cytokines and other proteins, such as CCL-17, CCL-22, TGF-β, IL-10, arginase 1, and galectin-3, make a significant contribution to immunosuppression. Since TAMs influence various aspects of cancer progression, there are many attempts to use them as a target for immunotherapy. The numerous studies have shown that the primary tumor growth and the number of metastatic sites can be significantly decreased by decreasing the population of macrophages in tumor tissue, for example, by blocking recruitment of monocytes or eliminating TAMs already present in the tumor tissue. Moreover, there are attempts at reprogramming TAMs into proinflammatory M1 macrophages or neutralizing the protumoral products of TAMs. Another approach uses TAMs for anticancer drug delivery into the tumor environment. In this review, we would like to summarize the clinical and preclinical trials that were focused on macrophages as a target for anticancer therapies.
      datePublished:2017-06-28T00:00:00Z
      dateModified:2017-06-28T00:00:00Z
      pageStart:97
      pageEnd:111
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00005-017-0480-8
      keywords:
         Tumor-associated macrophages
         TAMs
         Cancer therapies
         Immunotherapy
         Tumor
         Immunology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Archivum Immunologiae et Therapiae Experimentalis
         issn:
            1661-4917
            0004-069X
         volumeNumber:66
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Katarzyna Sawa-Wejksza
            url:http://orcid.org/0000-0001-5495-1838
            affiliation:
                  name:Maria Curie-Skłodowska University
                  address:
                     name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Martyna Kandefer-Szerszeń
            affiliation:
                  name:Maria Curie-Skłodowska University
                  address:
                     name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Archivum Immunologiae et Therapiae Experimentalis
      issn:
         1661-4917
         0004-069X
      volumeNumber:66
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Maria Curie-Skłodowska University
      address:
         name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
         type:PostalAddress
      name:Maria Curie-Skłodowska University
      address:
         name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Katarzyna Sawa-Wejksza
      url:http://orcid.org/0000-0001-5495-1838
      affiliation:
            name:Maria Curie-Skłodowska University
            address:
               name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Martyna Kandefer-Szerszeń
      affiliation:
            name:Maria Curie-Skłodowska University
            address:
               name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland
      name:Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland

External Links {🔗}(545)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.5s.

LINK . SPRINGER . COM {}